- Home
- QTI vs VRAX Comparison
QTI vs VRAX Comparison
Compare QTI & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTI
- VRAX
- Stock Information
- Founded
- QTI 2012
- VRAX 2013
- Country
- QTI United States
- VRAX United Kingdom
- Employees
- QTI N/A
- VRAX N/A
- Industry
- QTI
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- QTI
- VRAX Health Care
- Exchange
- QTI NYSE
- VRAX Nasdaq
- Market Cap
- QTI 8.7M
- VRAX 7.8M
- IPO Year
- QTI N/A
- VRAX 2022
- Fundamental
- Price
- QTI $0.42
- VRAX $1.75
- Analyst Decision
- QTI
- VRAX
- Analyst Count
- QTI 0
- VRAX 0
- Target Price
- QTI N/A
- VRAX N/A
- AVG Volume (30 Days)
- QTI 192.0K
- VRAX 369.4K
- Earning Date
- QTI 11-13-2024
- VRAX 02-05-2025
- Dividend Yield
- QTI N/A
- VRAX N/A
- EPS Growth
- QTI N/A
- VRAX N/A
- EPS
- QTI N/A
- VRAX N/A
- Revenue
- QTI $4,037,118.00
- VRAX $84,872.00
- Revenue This Year
- QTI N/A
- VRAX $5,169.18
- Revenue Next Year
- QTI N/A
- VRAX $66.97
- P/E Ratio
- QTI N/A
- VRAX N/A
- Revenue Growth
- QTI 10884.16
- VRAX 7.03
- 52 Week Low
- QTI $0.37
- VRAX $0.60
- 52 Week High
- QTI $14.40
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- QTI 40.05
- VRAX 47.01
- Support Level
- QTI $0.37
- VRAX $1.51
- Resistance Level
- QTI $0.52
- VRAX $2.38
- Average True Range (ATR)
- QTI 0.05
- VRAX 0.22
- MACD
- QTI -0.01
- VRAX 0.02
- Stochastic Oscillator
- QTI 27.78
- VRAX 27.25
About QTI QT IMAGING HOLDINGS INC
QT Imaging Holdings Inc is engaged in the research, development and commercialization of an automated breast imaging system producing high-resolution transmission ultrasound images.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.